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Background: Recreational marathon runners face strong physiological challenges.
Assessment of potential biomarkers for the biological responses of runners will help
to discriminate individual race responsiveness and their physiological consequences.
This study sought to analyze the changes in the plasma levels of GDF15 and FGF21,
novel endocrine factors related to metabolic stress, in runners following the strenuous
exercise of a marathon race.
Methods: Blood samples were obtained from eighteen male runners (mean ±SD, age:
41.7 ±5.0 years, BMI: 23.6 ± 1.8) 48 h before, immediately after, and 48 h after
a marathon race, and from age-matched sedentary individuals. The level of GDF15,
FGF21, and 38 additional biochemical and hematological parameters were determined.
Results: The basal levels of GDF15 and FGF21 did not differ between runners before
the race and sedentary individuals. Significant increases in the mean levels of GDF15
(4.2-fold) and FGF21 (20-fold) were found in runners immediately after the race. The
magnitudes of these increases differed markedly among individuals and did not correlate
with each other. The GDF15 and FGF21 levels had returned to the basal level 48 h post-
race. The post-race value of GDF15 (but not FGF21) correlated positively with increased
total white cell count (r = 0.50, P = 0.01) and neutrophilia (r = 0.10, P = 0.01).
Conclusion: GDF15 and FGF21 are transiently increased in runners following a
marathon race. The induction of GDF15 levels is associated with alterations in circulating
immune cells levels.
Keywords: strenuous exercise, GDF15, FGF21, marathon athletes, biomarker
INTRODUCTION
Recreational running is a widespread activity and the marathon (a 42.2-km running race named
for the Greek legend) is growing in popularity, with modern-day marathons drawing thousands
of contestants. Recreational marathon runners face strong physiological challenges and multiple
studies have reported alterations in physiological parameters and associated blood parameters
Frontiers in Physiology | www.frontiersin.org 1 November 2020 | Volume 11 | Article 550102
fphys-11-550102 November 13, 2020 Time: 14:19 # 2
Campderrós et al. GDF15 and FGF21 in Marathon Runners
during and after a marathon race (Kratz et al., 2002; Reid et al.,
2004; Kobayashi et al., 2005; Bird et al., 2014). The commonly
reported findings include increased levels of biomarkers for
exertional myolysis as well as increased neutrophilia and
monocytosis (Kratz et al., 2002; Bird et al., 2014). Additional
biomarkers are needed to help discriminate differential individual
race responsiveness.
Growth/differentiation factor-15 (GDF15), which is also
called macrophage inhibitor (MIC-1) and non-steroidal anti-
Inflammatory drug-activated gene-1 (NAG-1), is a member of
the TGFβ superfamily. Although the functional role of GDF15
is not fully known, elevated GDF15 levels in blood have been
reported as a biomarker of several pathological conditions, such
as cancer, inflammatory disorders, cardiovascular disease and
type 2 diabetes, and as a biomarker of mortality of any kind
(Adela and Banerjee, 2015; Hagström et al., 2017; Tsai et al.,
2018). The lack of an identified GDF15 receptor previously
hampered efforts to assess the physiological role of GDF15 but
recent work identified a receptor for GDF15 (GFRAL) in brain,
and showed that it accounts for the anorexigenic actions of
GDF15 (Emmerson et al., 2017; Hsu et al., 2017; Mullican et al.,
2017; Yang et al., 2017). GDF15 has been reported to exert anti-
inflammatory actions of GDF15 in peripheral cell systems, such
as eosinophils and macrophages (Bootcov et al., 1997; Artz et al.,
2016), via yet-unidentified receptor systems.
Elevated GDF15 levels have been reported as a biomarker of
neuromuscular diseases of genetic origin caused by alterations
in the mitochondrial genome (Fujita et al., 2015; Yatsuga et al.,
2015). Indeed, experimentally induced alterations in muscle cell
mitochondrial bioenergetics reportedly trigger enhancements in
GDF15 gene expression and muscle cell release (Montero et al.,
2016). In this sense, the secretion of GDF15 in muscle parallels
that of fibroblast growth factor-21 (FGF21), which was recently
proposed to be a biomarker of diseases caused by mitochondrial
DNA mutations (Suomalainen et al., 2011; Ribas et al., 2014). In
children affected by distinct mitochondrial diseases, the levels of
GDF15 and FGF21 levels are increased and highly correlated with
one another (Montero et al., 2016).
Numerous studies have reported that FGF21 levels increase
in response to experimental acute exercise (Cuevas-Ramos et al.,
2012; Kim et al., 2013; Hansen et al., 2015, 2016; Slusher et al.,
2015; Tanimura et al., 2016; Morville et al., 2018; Sargeant
et al., 2018). GDF15 has also been reported to exhibit transient
elevations following an experimental single bout of exercise
(Kleinert et al., 2018), a cycling race (Conte et al., 2020) and
relatively time-limited sports activities such as a soccer match
(Sanchis-Gomar et al., 2013) or a training session of rugby players
(Galliera et al., 2014). Increased levels of GDF15 in athletes
immediately after a 247-km race (the so-called Spartathlon) has
also been reported (Tchou et al., 2009). However, the literature
lacks a thorough characterization of changes in GDF15 and
their comparison with FGF21 following a marathon race, which
is the most commonly practiced recreational race involving
strenuous exercise.
Given the potential roles of FGF21 and GDF15 in the
physiological response to exercise, we wanted to explore
whether these factors could contribute to the assessment of the
physiological response to a marathon race. Here, we determined
the levels of GDF15 and FGF21 in marathon runners before
race (basal levels), immediately after the race (acute response
to strenuous exercise) and 2 days after the race (short time
recovery). We also sought to correlate these data with standard
parameters previously reported to be altered in athletes after a
marathon race (Kratz et al., 2002; Reid et al., 2004; Kobayashi
et al., 2005; Bird et al., 2014).
METHODS
The study was designed to analyze the changes of GDF15 and
FGF21 levels in recreational athletes before and after a marathon
race held at Barcelona on March 17, 2017.
Volunteers were recruited as part of the “SUMMIT project”
(“Health in Ultra-Marathon and their Limits”), which sought
to evaluate the behavior of certain clinical parameters among
runners competing in different races. The SUMMIT project was
approved by an institutional review board (IIBSP-SUMMIT-
2016-2) and all participants provided written informed consent
to the current study. The study sample included 18 recreational
male athletes (mean± SD age: 41.7± 5.0 years, BMI: 23.6± 1.8).
Sample size was dependent on availability of volunteers and was
not based on power calculations; however, sample size was in
the range of that resulting from power calculations in studies
of individuals at rest and after a single bout of exercise (Yatsuga
et al., 2015; Poulsen et al., 2020). The median (interquartile range,
IQR) years of training was 7 (5–11) years and the median (IQR)
of weekly training hours was 6 (5–8) h/week. The median (IQR)
race time (h:min:s) was 3:32:44 (3:18:50–3:51:46).
The participants were provided with guidelines to maintain
adequate levels of hydration during the race. The first liquid
intake was programmed at 60 min of the race; the dosage
consisted of 400 ml for lighter/slower runners and 800 ml
for heavier/faster runners, and runners were asked to drink
100–150 ml every 15–20 min. Commercialized beverages were
provided to participants; the drinks averaged 480 mg/L for Na+,
85 mg/L for K+, and 45 mg/L for Mg2+.
Three 10-mL blood samples were obtained from the
antecubital vein in EDTA vacutainers at 48 h before the marathon
(baseline), at completion (within the 10 min of an individual
completing the race and before they drank any fluid or emptied
the bladder) and 48 h after the race. Blood samples were
centrifuged at 3,000 rpm at 4◦C for 10 min in a bench-top
centrifuge. Serum samples were aliquoted and stored on dry ice,
and all samples were frozen at−80◦C.
Biochemical and hematological parameters were determined
in blood at the Clinical Biochemistry and Hematology facilities at
Hospital Germans Trias i Pujol (Badalona, Spain). Blood glucose
lipids, urea, total protein, ions, alanine aminotransferase (ALT),
aspartate aminotransferase (AST), lactate dehydrogenase (LDH),
and gamma-glutamyl transpeptidase (GGT) were analyzed by
routine clinical chemistry and using an AU-5800 Chemistry
Analyzer (Beckman Coulter Inc., Brea, CA, United States).
Complete blood counts were obtained using a Unicel DxH800
automated hematology analyzer (Beckman Coulter, Miami,
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FL, United States). Troponin T was measured from serum,
using a Highly Sensitive Troponin-T assay on a Cobas e601
platform (Roche Diagnostics, Barcelona, Spain). The inter-
assays coefficients of variation (CV) in the analytical assays
are shown in Supplementary Table 1. FGF21 levels (intra-
assay CV 2.0%, inter-assay CV 3.3%) and GDF15 levels (intra-
assay CV 2.6%, inter-assay CV 5.3%) were measured using
human-specific ELISA kits (R&D Systems, United Kingdom,
and Biovendor, Czechia, respectively). For comparison purposes,
an age-matched and BMI-matched group of healthy male
volunteers, with a sedentary behavioral profile (no recreational
or relevant occupational-related exercise activity), was recruited
among personnel of the University of Barcelona (N = 19,
mean± SD age: 41.4± 3.0 years) and studied.
The normality of distribution of the variables was checked
by the Shapiro–Wilk test and the homogeneity of variances
was assessed by Levene’s test. Repeated-measures ANOVA test
was used to determine the effect of the marathon on variables
measured at 24 h pre-race, immediately post-race and 48 h post-
race using the multiple-comparison Bonferroni tests. Pearson
correlation coefficient was applied according to the normal
distribution of variables. The level of statistical significance
was set at P < 0.05. IBM R© SPSS R© version 24.0 (Armonk, NY,
United States) was used for data analysis.
RESULTS
Immediately after the race, the participating runners showed
an increase in their total white blood cell (WBC) count;
this was associated with increased numbers of neutrophils,
monocytes, and basophils but reduced numbers of lymphocytes
and eosinophils (Table 1). These changes were totally reversed at
48 h after the race, when the values for these parameters were not
statistically different from the basal values. Significant increases
were also observed in the levels of urea, creatinine, calcium, total
protein, sodium, potassium, and bilirubin immediately after the
race; all of these parameters also returned to basal levels with
the exception of potassium, which remained high at 48 h post-
race, and total protein which was decreased below the basal
level at 48 h post-race. The magnesium and phosphorus levels
were transiently reduced after the race and normalized totally
(magnesium) or partially (phosphorus) 48 h later. The levels of
LDH and troponin were significantly induced immediately after
the race; at 48 h after the race, troponin had returned to the basal
level whereas LDH remained significantly elevated. The creatine
kinase level was significantly higher immediately after the race
compared to basal level and was further increased at 48 h post-
race. Finally, the levels of ALT and C-reactive protein levels were
increased relative to their basal levels only at 48 h post-race.
The basal levels of plasma GDF15 and FGF21 did not
significantly differ between pre-race athletes and sedentary
individuals (Figure 1A), indicating that chronic training does
not influence the basal levels of these two bioactive factors.
Immediately after the race, the levels of both GDF15 and FGF21
levels were dramatically increased in athletes; there was a 4.2-fold
increase in the mean GDF15 level and a ∼20-fold increase in the
mean FGF21 level (Figure 1A), and the extents of these increases
differed markedly among the studied individuals (Figure 1B).
The plasma levels of GDF15 and FGF21 had returned to near-
basal levels at 48 h post-race. There was no significant correlation
in the basal levels of GDF15 and FGF21 or the extent of their
increases immediately after the race (Table 2). There was also no
significant correlation between the increase of GDF15 or FGF21
and the time spent in the race or any other race-related variable.
Among the 32 distinct physiological and blood biochemical
and hematological parameters tested herein, the basal (pre-
race) level of GDF15 was positively correlated with that of ALT
(Supplementary Table 2) and the GDF15 level immediately
after the race was positively correlated with the WBC count,
neutrophil count, urea level, and ALT level (Table 2). The basal
levels of FGF21 correlated positively with the WBC count, platelet
count, monocyte count, total protein level, and C-reactive protein
level (Supplementary Table 2), and correlated negatively with the
urea level. The peak levels of FGF21 observed just after the race
correlated positively with glycemia and the total protein levels,
with marginal statistically significance (Table 2).
DISCUSSION
Overall, the alterations in blood parameters observed in the
current study are largely concordant with previous findings
on the physiological response to marathon running. We found
increases in the levels of total protein, urea, creatinine, bilirubin,
creatine kinase, LDH, and troponin after the race; these findings
paralleled those of a previous study in marathon runners (Bird
et al., 2014) and were consistent with a scenario of exertional
muscle injury and hemolysis. Some of these parameters returned
to their basal values by 48 h post-race, whereas others (e.g.,
creatine kinase, LDH, and troponin) did not; again, this was
consistent with previous reports (Kobayashi et al., 2005; Bird
et al., 2014). We also confirmed that the increase in total WBC
count was mainly due to increased numbers of neutrophils
and monocytes (Kratz et al., 2002; Reid et al., 2004), which is
commonly attributed to an inflammatory reaction to exertion-
related tissue injury.
Regarding our novel results, we herein report that the plasma
levels of GDF15 and FGF21 were both increased immediately
after the marathon race and returned to normal levels within
48 h post-race. The extent of these transient bursts in GDF15
and FGF21 concentration was very variable among individuals,
was not associated with any of the studied intrinsic exercise-
associated traits (i.e., extent of prior training, duration of the race,
etc.), and the degrees to which GDF15 and FGF21 increased were
not correlated with each other in studied runners.
This is one of only a few studies to focus on how exercise affect
the level of GDF15. Studies performed in soccer players after
a match and rugby players after training reported a significant
increase in GDF15 levels in blood (Sanchis-Gomar et al., 2013;
Galliera et al., 2014), and a recent experimental study showed that
there was a significant rise in GDF15 levels among volunteers
who exercised at 67% of their VO2max for 1 h (Kleinert et al.,
2018). In these reports, the increase in GDF15 was around 1.5- to
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2-fold, which is much less than the more than fourfold increase
found here after marathon race-associated strenuous exercise.
Only a study in spartathlon runner found a rise in GDF15 levels in
the fourfold range found here for marathon runners (Tchou et al.,
2009) whereas around threefold increase in GDF51 levels were
reported after a long distance cycling race (Conte et al., 2020).
During the editorial processing of the current article, a study
in Marathon runners in Poland has been reported (Kaleta-Duss
et al., 2020) showing a rise in GDF15 levels immediately after
the race and normalization thereafter, confirming our findings.
In that study, focused to cardiovascular markers, a significant
increase in the biomarkers of altered cardiac function BNP,
NT-proANP, H-FABP, and Gal-3 immediately after the race
was also found; however, they did not correlate with GDF15.
Although the rise in GDF15 may be related to changes in cardiac
hemodynamic volume and pressure overload immediately after
the marathon, it has been proposed that GDF15 does not appear
as reliable to track specifically cardiorespiratory fitness in acute
exercise, possibly because of the contribution of other non-
cardiac processes to the GDF15 rise in exercise (Kaleta-Duss
et al., 2020). Nonetheless, some authors found GDF15 levels to
be associated with impairment in exercise capacity in patients
with the heart failure syndrome (Stahrenberg et al., 2010) whereas
others do not consider GDF15 as a reliable biomarker of exercise
capacity in heart failure patients (Fudim et al., 2020).
Concerning FGF21, the previous studies reported –twofold to
fourfold increases in FGF21 after experimental bouts of acute
exercise (1–3 h) (Kim et al., 2013; Hansen et al., 2015, 2016;
TABLE 1 | Circulating parameters measured before (pre-marathon), immediately after (post-marathon) and 48 h after the marathon race.
Pre-marathon Post-marathon 48 h Post-marathon
Age (years) 41.71 ± 1.04
Weight (kg) 76.15 ± 1.35
White blood cell count (±109/L) 6.28 ± 0.30 13.55 ± 0.65*** 5.70 ± 0.30###
Red blood cell count (±106/µL) 5.06 ± 0.10 5.04 ± 0.09 4.89 ± 0.09
Mean corpuscular hemoglobin concentration (µ/dL) 33.25 ± 0.13 33.33 ± 0.11 32.77 ± 0.14*##
Hemoglobin (g/dL) 14.64 ± 0.21 14.63 ± 0.18 14.02 ± 0.17*
Hematocrit (%) 44.06 ± 0.62 43.86 ± 0.54 42.80 ± 0.50
Mean corpuscular volume (fL) 87.44 ± 0.91 87.27 ± 0.86 87.83 ± 0.86
Mean corpuscular hemoglobin (pg) 29.09 ± 0.37 29.09 ± 0.36 28.81 ± 0.36
Platelets (x103/µL) 188.30 ± 7.34 218.30 ± 10.23* 184.30 ± 7.93#
Neutrophils (x109/L) 3.47 ± 0.20 11.41 ± 0.60*** 3.06 ± 0.17###
Lymphocytes (x109/L) 2.00 ± 0.08 1.16 ± 0.07*** 1.84 ± 0.11###
Monocytes (x109/L) 0.46 ± 0.02 0.78 ± 0.06*** 0.43 ± 0.03###
Eosinophils (x109/L) 0.16 ± 0.02 0.02 ± 0.007*** 0.14 ± 0.02###
Basophils (x109/L) 0.02 ± 0.01 0.06 ± 0.01* 0.01 ± 0.006###
Glucose (mg/dL) 85.96 ± 2.26 85.96 ± 4.11 81.62 ± 2.26
Urea (mg/dL) 35.96 ± 1.80 42.63 ± 1.62* 35.26 ± 1.47##
Creatinine (mg/dL) 0.96 ± 0.02 1.25 ± 0.04*** 0.93 ± 0.02###
Calcium (mg/dL) 9.42 ± 0.06 9.92 ± 0.09*** 9.29 ± 0.06###
Magnesium (mmol/L) 2.02 ± 0.03 1.77 ± 0.03*** 2.05 ± 0.03###
Phosphorus (mg/dL) 3.58 ± 0.11 2.86 ± 0.15*** 3.16 ± 0.09*
Total protein (g/L) 72.72 ± 0.63 76.59 ± 0.76*** 69.54 ± 0.54**###
Sodium (mmol/L) 139.20f ± 0.20 141.90 ± 0.51*** 139.10 ± 0.26###
Potassium (mmol/L) 4.24 ± 0.05 4.45 ± 0.06** 4.41 ± 0.05*
Total bilirubin (mg/dL) 0.69 ± 0.04 0.88 ± 0.04** 0.72 ± 0.03 #
Alkaline phosphatase (U/L) 74.12 ± 3.07 78.81 ± 3.36 69.0 ± 3.52
Gamma-glutamyl transpeptidase (U/L) 20.12 ± 1.65 20.69 ± 1.43 18.62 ± 1.26
Alanine aminotransferase (U/L) 22.59 ± 1.70 24.44 ± 1.57 33.73 ± 2.71***##
Lactate dehydrogenase (U/L) 186.6 ± 5.03 324.7 ± 14.50*** 228.7 ± 9.00*###
Creatine kinase (U/L) 170.3 ± 15.58 397.0 ± 28.99* 802.6 ± 107***###
Troponin (ng/L) 3.92 ± 0.67 31.88 ± 5.03*** 5.87 ± 0.88###
C-reactive protein (mg/dL) 0.89 ± 0.15 0.64 ± 0.09 6.81 ± 0.78***###
Triglycerides (mg/dL) 105.3 ± 8.85 100.4 ± 5.67 82.15 ± 8.81
Cholesterol (mg/dL) 186.3 ± 7.43 185.0 ± 6.60 172.9 ± 6.13
GDF15 (pg/mL) 372.8 ± 21.20 1,164 ± 124.7*** 347.6 ± 15.82###
FGF21 (pg/mL) 20.24 ± 7.33 770.3 ± 130.2*** 39.52 ± 11.77###
*P < 0.05, **P < 0.01, and ***P < 0.001 relative to the measurements before the race and #P < 0.05, ##P < 0.01, and ###P < 0.001 relative to the measurements
immediately after the race. Bold lettering is shown when P < 0.05.
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FIGURE 1 | Levels of GDF15 and FGF21 in marathon runners 48 h before the race (pre-marathon), immediately after the race (post-marathon) and 48 h after the
race, and comparison with levels in a sedentary control population. (A) Box and whisker plot representation of GDF15 and FGF21 levels, ***P < 0.001 relative to
pre-marathon values. (B) Individual changes in the levels of GDF15 and FGF21 in the three time points analyzed. Gray bar corresponds to means + SEM values in
the sedentary control population.
Slusher et al., 2015; Morville et al., 2018; Sargeant et al., 2018),
whereas we observed a much greater increase of around 20-fold
in the level of FGF21 immediately after the runners completed
the marathon race.
It is worth mentioning that, beyond exercise, the blood
levels of GDF15 and FGF21 are also increased in pathological
contexts, such as in patients affected by neuromuscular diseases
caused by mitochondria DNA mutations (Suomalainen et al.,
2011). Moreover, GDF15 and FGF21 were reported to be
actively released by human muscle cells after experimental
mitochondrial insults in vitro (Ribas et al., 2014; Montero et al.,
2016). However, not all the above mentioned studies found
correlations between the high levels of GDF15 and FGF21 in
patients, and it has been proposed that GDF15 may have value
as a biomarker of muscle damage, whereas FGF21 may be
more strongly associated with mitochondrial-specific pathologies
(Lehtonen et al., 2016).
The lack of correlation between the bursts of the two molecules
reported here suggests that distinct physiological processes (and
possibly tissues of origin) are involved in these increases. Given
that the increase in FGF21 is associated with decreased glycemia
and the liver is the main site of FGF21 release under physiological
conditions, it is likely that the liver was the main source of
the FGF21 increase seen immediately after the marathon race.
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This has been proposed for other exercise-induced changes in
FGF21 levels and it is consistently with the behavior of other
hepatokines (Weigert et al., 2019). For GDF15, a recent study
indicated that the rise in GDF15 after a single bout of exercise
is associated with increased GDF15 gene expression in skeletal
muscle (Laurens et al., 2020). From this, we hypothesize that
muscle may be the source of the high-level induction of GDF15
seen immediately after the marathon race, although correlation
with ALT levels does not allow to rule out a potential role of
hepatic stress contributing to high GDF15 levels. Further studies
are clearly required in order to identify the tissue sources that lead
to the rise in GDF15 and FGF21 levels in marathon runners. This
may be relevant in order to identify critical sites of tissue stress
due to the race indistinct individuals according to their rise in the
GDF15 and/or FGF21 biomarkers.
Our study has several limitations. The sample is relatively
small and limited to recreational runners, and further data
on the characteristics of individuals beyond biochemical and
hematological data (e.g., body composition, performance level,
pacing, and internal load) could have strengthened the study.
The correlative nature of some of our findings is also an obvious
limitation. However, our data allow us to conclude that: (a)
both GDF15 and FGF21 are dramatically induced immediately
after the strenuous exercise associated with a marathon race;
(b) the extents to which GDF15 and FGF21 are induced are
highly variable among runners and do not correlate with each
other; (c) both parameters recover to baseline within 2 days post-
race; and (d) the rises in GDF15 and FGF21 immediately after
the race are distinctly correlated with alterations in biochemical
and hematological biomarkers of the physiological response
TABLE 2 | Linear relationship of the post-marathon GDF15 levels and FGF21 levels with the post-marathon levels of circulating parameters.
GDF15 FGF21
r P r P
GDF15 – – 0.394 0.106
FGF21 0.394 0.106 – –
White blood cell count (×109/L) 0.455 0.022* 0.930 0.237
Red blood cell count (×106/µL) −0.067 0.751 −0.237 0.343
Mean corpuscular hemoglobin concentration (g/dL) −0.129 0.539 0.061 0.811
Hemoglobin (g/dL) −0.054 0.799 −0.202 0.422
Hematocrit (%) −0.015 0.942 −0.217 0.387
Mean corpuscular volume (fL) 0.113 0.591 0.149 0.555
Mean corpuscular hemoglobin (pg) 0.058 0.782 0.134 0.596
Platelets (×103/µL) 0.084 0.689 0.374 0.126
Neutrophils (×109/L) 0.506 0.010** 0.314 0.205
Lymphocytes (×109/L) −0.225 0.279 −0.059 0.816
Monocytes (×109/L) 0.326 0.112 0.319 0.198
Eosinophils (×109/L) −0.368 0.071 −0.152 0.547
Basophils (×109/L) 0.241 0.247 0.050 0.843
Glucose (mg/dL) −0.136 0.518 −0.470 0.049*
Urea (mg/dL) 0.661 0.0003*** 0.004 0.989
Creatinine (mg/dL) 0.349 0.087 0.103 0.684
Calcium (mg/dL) 0.122 0.560 0.155 0.539
Magnesium (mmol/L) 0.062 0.770 −0.038 0.881
Phosphorus (mg/dL) −0.129 0.541 −0.461 0.055
Total protein (g/L) 0.140 0.504 0.479 0.044*
Sodium (mmol/L) −0.166 0.429 −0.069 0.786
Potassium (mmol/L) 0.373 0.066 0.212 0.398
Total bilirubin (mg/dL) 0.214 0.305 −0.054 0.832
Alkaline phosphatase (U/L) 0.230 0.268 −0.238 0.341
Gamma-glutamyl transpeptidase (U/L) −0.064 0.761 0.325 0.189
Alanine aminotransferase (U/L) 0.498 0.011* 0.240 0.338
Lactate dehydrogenase (U/L) 0.157 0.452 0.156 0.536
Creatine kinase (U/L) −0.227 0.275 −0.382 0.118
Troponin (ng/L) 0.142 0.498 −0.236 0.345
C-reactive protein (mg/dL) 0.011 0.958 0.176 0.485
Triglycerides (mg/dL) 0.162 0.439 0.304 0.220
Cholesterol (mg/dL) −0.219 0.292 −0.255 0.308
Statistical significance is from Pearson correlation test. *P < 0.05, **P < 0.01, and ***P < 0.001. Bold lettering is shown when P < 0.05.
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to exercise. Further research is needed to ascertain whether
the strong intra-individual differences in the extent of GDF15
and FGF21 induction among runners can predict underlying
adaptations and/or the risk for long-term damaging responses to
the strenuous exercise associated with a marathon race.
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